Vanda Pharmaceuticals Announces FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study

Vanda Pharmaceuticals reports that the FDA has lifted a partial hold on its Tradipitant motion-sickness study. Tradipitant is a drug candidate being developed for the treatment of motion sickness. The partial hold was previously placed due to concerns about a potential increase in the incidence of QT interval prolongation.